drugset / Trial / NCT00226707

Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

NCT00226707

Phase 3 Completed 652 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.

Timeline

Start
2004-07
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimecrolimus Small molecule 1 %

Indications